Top 10 Companies in the (Bromomethyl)cyclohexane (CAS 2033-36-9) Market (2026): Market Leaders Powering Global Demand

MARKET INSIGHTS

Global (Bromomethyl)cyclohexane (CAS 2033-36-9) market size was USD 28.4 million in 2025 and is projected to rise to USD 46.2 million by 2034, reflecting a 5.1 % CAGR over the forecast period.

(Bromomethyl)cyclohexane (CAS 2033-36-9) is an organobromine compound with the molecular formula C₆H₁₁Br. Its cyclohexane core and bromomethyl substituent make it a highly reactive alkylating agent, frequently employed as a key intermediate in the synthesis of pharmaceuticals, agrochemicals, and specialty chemicals. The reagent’s capacity to undergo nucleophilic substitution reactions enables the construction of complex carbon frameworks that underpin many modern drug and agrochemical molecules.

The market is driven by a steady rise in demand for fine chemicals and active pharmaceutical ingredients, with (Bromomethyl)cyclohexane serving as a critical building block. Expanding agrochemical formulation activities and increased investment in chemical R&D worldwide reinforce this momentum. Leading suppliers—TCI Chemicals, Sigma‑Aldrich (Merck KGaA), and Alfa Aesar—maintain extensive catalogues that cater to both research and industrial‑scale applications.

(Bromomethyl)cyclohexane (CAS 2033-36-9) Market – View in Detailed Research Report

Top 10 Companies in the (Bromomethyl)cyclohexane (CAS 2033-36-9) Market

1. MilliporeSigma (Germany)

Headquarters: Darmstadt, Germany
Key Offering: High‑purity alkylating agents for pharmaceutical intermediates

MilliporeSigma’s integrated manufacturing network delivers reagents that meet the strict purity standards demanded by drug discovery programmes. The company’s emphasis on process robustness and scalability ensures consistent supply for high‑volume API synthesis.

Sustainability Initiatives:

• Investment in green chemistry protocols to reduce hazardous waste
• Carbon‑neutral production targets for 2030
• Partnerships with academic research centres to validate eco‑friendly routes

2. Tokyo Chemical Industry Co., Ltd. (TCI)

Headquarters: Tokyo, Japan
Key Offering: Specialty organobromine reagents for pharma and agrochemical synthesis

TCI’s production facilities are optimized for high‑yield bromination, enabling cost‑effective supply of (Bromomethyl)cyclohexane to both domestic and export markets.

Sustainability Initiatives:

• Waste‑minimization programmes across all sites
• Renewable energy utilisation in core manufacturing units
• Compliance with Japan’s stringent environmental regulations

3. Oakwood Products, Inc.

Headquarters: New York, USA
Key Offering: Bulk chemical manufacturing of brominated intermediates

Oakwood focuses on delivering cost‑efficient, high‑volume supplies of (Bromomethyl)cyclohexane to the North American market, supporting a range of API and specialty chemical projects.

Sustainability Initiatives:

• Process optimisation to lower energy consumption
• Implementation of closed‑loop solvent recovery
• Hazardous waste reduction targets for 2028

4. Enamine LLC

Headquarters: Kharkiv, Ukraine
Key Offering: Custom synthesis of organobromine reagents for research and industrial clients

Enamine’s modular synthesis platform allows rapid turnaround of bespoke (Bromomethyl)cyclohexane derivatives, catering to niche research projects and small‑batch API production.

Sustainability Initiatives:

• Adoption of biocatalytic bromination methods
• Use of renewable feedstocks where feasible
• Carbon footprint monitoring across all operations

5. Biosynth Carbosynth

Headquarters: Switzerland
Key Offering: Small‑molecule synthesis services with a focus on organobromine intermediates

Biosynth Carbosynth provides a catalogue of high‑purity reagents and custom synthesis services, supporting medicinal chemistry and agrochemical R&D.

Sustainability Initiatives:

• Use of green solvents in all synthetic routes
• Closed‑loop process designs to minimise waste
• Participation in EU circular economy initiatives

6. Apollo Scientific Ltd.

Headquarters: London, UK
Key Offering: Research chemicals with ultra‑high purity for pharmaceutical development

Apollo Scientific delivers reagents that comply with REACH and other regulatory frameworks, ensuring seamless integration into drug discovery pipelines.

Sustainability Initiatives:

• Compliance with European safety and environmental standards
• Investment in low‑energy manufacturing technologies
• Strategic sourcing of sustainable raw materials

7. ChemDiv, Inc.

Headquarters: Philadelphia, USA
Key Offering: Specialty chemicals for pharmaceutical intermediates and fine chemicals

ChemDiv’s expertise in scale‑up and process optimisation supports clients seeking reliable supply of (Bromomethyl)cyclohexane for complex synthesis routes.

Sustainability Initiatives:

• Renewable feedstock integration in production lines
• Energy‑efficiency upgrades across all facilities
• Zero‑waste targets for 2030

8. Finetech Industry Limited

Headquarters: Shanghai, China
Key Offering: Bulk production of organobromine intermediates for domestic and export markets

Finetech’s large‑scale operations provide cost‑effective supply for the growing Chinese and ASEAN pharmaceutical sectors.

Sustainability Initiatives:

• Automation of bromination processes to reduce energy use
• Investment in wastewater treatment infrastructure
• Emission control programmes aligned with national regulations

9. Hebei Yanxi Chemical Co., Ltd.

Headquarters: Shijiazhuang, China
Key Offering: Large‑scale bromination and API intermediate production

Hebei Yanxi serves both domestic and regional customers, offering high‑purity reagents for pharmaceutical and agrochemical applications.

Sustainability Initiatives:

• Implementation of industrial‑scale recycling of bromine waste
• Compliance with ISO 14001 environmental management standards
• Energy‑conservation measures across production units

10. Wuhan Kemi‑Works Chemical Co., Ltd.

Headquarters: Wuhan, China
Key Offering: High‑volume production of (Bromomethyl)cyclohexane for API synthesis

Kemi‑Works focuses on meeting the rising demand from China’s expanding pharmaceutical industry.

Sustainability Initiatives:

• Adoption of green chemistry principles in bromination
• Waste minimisation and recycling programmes
• Collaboration with local universities on process optimisation

Download FREE Sample Report

Get Full Report

Outlook

The market is poised to reach USD 46.2 million by 2034, driven by sustained demand for high‑purity reagents in pharmaceutical and agrochemical synthesis. The shift toward greener production methods—such as biocatalytic bromination and solvent‑free reactions—will help mitigate high production costs and support the entry of new players. Continued investment in automation and digital supply‑chain solutions is expected to improve throughput and reduce lead times, further strengthening the value chain.

Future Trends

• Adoption of bioorthogonal chemistry platforms that leverage (Bromomethyl)cyclohexane’s alkylating capability for advanced therapeutics.
• Expansion of custom synthesis services to meet the needs of precision medicine and personalized drug development.
• Increased focus on circular economy initiatives, including bromine recycling and waste‑stream minimisation.
• Emerging markets in Latin America and the Middle East will begin to contribute more significantly to global consumption as local production capacities mature.